Teva Pharmaceuticals @TevaUSA
Biosimilar medicines are potentially less expensive than original biologics, whilst having the same effectiveness. Teva’s Cory Wohlbach explains what #biosimilars are and how he is working with government regulators to share his expertise. #MeetOurExpert https://t.co/4C47sO037T https://t.co/8VNXjJMHWd — PolitiTweet.org